{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:48:51Z","timestamp":1788306531415,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.vaccine.2015.05.027","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T17:51:56Z","timestamp":1432835516000},"page":"3322-3330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers"],"prefix":"10.1016","volume":"33","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Kaczmarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.05.027_bib0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jinf.2014.01.003","article-title":"Safe laboratory handling of Neisseria meningitidis","volume":"65","author":"Borrow","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0220","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/jhin.2001.1084","article-title":"Risk of laboratory-acquired meningococcal disease","volume":"49","author":"Boutet","year":"2001","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0225","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2217\/fmb.10.137","article-title":"Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults","volume":"5","author":"Pace","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1179\/2047773213Y.0000000119","article-title":"An epidemiological review of changes in meningococcal biology during the last 100 years","volume":"107","author":"Abio","year":"2013","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0240","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/315284","article-title":"Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine","volume":"181","author":"Richmond","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0245","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunological refractoriness in adults by meningococcal C polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0250","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1128\/CVI.05020-11","article-title":"Meningococcal group C and W135 immunological hyporesponsiveness in African toddlers","volume":"18","author":"Findlow","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0255","first-page":"83","article-title":"Immunological hyporesponsiveness to group C but not group A following repeated meningococcal A\/C polysaccharide vaccination in Saudi Arabia","volume":"11","author":"Jokhdar","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0260","first-page":"272","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0265","first-page":"156","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0270","unstructured":"World Health Organization. Requirements for meningococcal polysaccharide vaccine. World Health Organisation Technical Series No. 594. Geneva: WHO; 1976."},{"key":"10.1016\/j.vaccine.2015.05.027_bib0275","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0280","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0285","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0290","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus: I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0295","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus: II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0300","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)92125-X","article-title":"Effect of group-A meningococcal vaccine in Army recruits in Finland","volume":"2","author":"Makela","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0305","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0310","unstructured":"Department of Health. Immunisation against infectious disease\u2014\u2018The Green Book\u2019. http:\/\/immunisation.dh.gov.uk\/category\/the-green-book\/ (2006)."},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2015.05.027_bib0315","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0320","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1128\/IAI.00466-06","article-title":"Comparison and correlation of Neisseria meningitidis serogroup B immunologic assays and human antibody responses following three doses of the \u2018Norwegian\u2019 meningococcal outer membrane vesicle vaccine, MenBvac","volume":"74","author":"Findlow","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0325","first-page":"26","article-title":"Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine","volume":"9","author":"Findlow","year":"2014","journal-title":"JOMT"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0330","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0335","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00102-07","article-title":"Seroprevalance of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England","volume":"14","author":"Trotter","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0340","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/S0264-410X(01)00050-0","article-title":"Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A\/C polysaccharide vaccine and vaccine-na\u00efve controls","volume":"19","author":"Borrow","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0345","first-page":"1100","article-title":"Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults","volume":"11","author":"Southern","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0350","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2010.11.064","article-title":"Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1","volume":"29","author":"Brunelli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0355","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Commanducci","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0360","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0370","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jtm.12180","article-title":"Immunogenicity and safety of concomitant administration of a combined hepatitis A\/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2014","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jtm.12164","article-title":"Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2014","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0380","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicentre, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life- a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0390","first-page":"760","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"PIDJ"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0395","first-page":"614","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in Healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolayla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0400","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0405","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.05.027_bib0410","unstructured":"ClinicalTrials.gov identifier: NCT01272180. www.clinicaltrials.gov (accessed 09.01.2015)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15006593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15006593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:46Z","timestamp":1759400506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15006593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0264410X15006593"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2015 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}